drugset / Trial / NCT03068650

Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

NCT03068650

Expanded access No longer available Celldex Therapeutics

Summary

Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject rindopepimut Vaccine

Indications